1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 1: 
Consensus recommendations for the dosage of GPIIb/IIIa receptor inhibitors18-26
AgentTirofibanEptifibatideAbciximab
Loading dose (IV or IA bolus)12 mcg/kg for30 mina180 mcg/kg for 1–2 min0.25 mg/kg
Maintenance dose (if necessary, IV infusion for 12–24 hours)0.1 mcg/kg/min2 mcg/min0.125 mcg/kg/min
Trade nameAggrastatIntegrilinReoPro
Duration of antiplatelet effect4–8 hours4 hours48 hours
  • Note:—IA indicates intra-arterial.
  • ↵a 0.4 mcg/kg/min.